Type your tag names separated by a space and hit enter

Pemphigoid Gestationis

Pemphigoid Gestationis is a topic covered in the 5-Minute Clinical Consult.

To view the entire topic, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Explore these free sample topics:

Medicine Central

-- The first section of this topic is shown below --

Basics

Uncommon pregnancy-associated autoimmune bullous disease

Description

  • Pemphigoid gestationis (PG) is a rare dermatopathic autoimmune-mediated, self-limited eruption most often occurring during midpregnancy in the periumbilical region.
  • Onset
    • Most commonly begins in 2nd or 3rd trimester of pregnancy, waning just prior to delivery and then flaring after delivery; can occur at any time in pregnancy and postpartum period
    • Often recurs in subsequent pregnancies (likely earlier onset and more severe)
  • Characterized by intense pruritus followed by polymorphous papules and vesicles coalescing into bullae
    • Often periumbilical or with other truncal foci
    • May also affect the buttocks, forearms, palms, or soles
    • Less frequently, scalp and face are involved.
    • Mucous membranes are typically spared, but intestinal mucosa may have celiac-like lesions without significant clinical malabsorption.
  • Pruritus may precede lesions by days to weeks.
  • System(s) affected: immune; skin; reproductive
  • Synonym(s): herpes gestationis; dermatitis gestationis

Epidemiology

Incidence
  • Rare: ~1/50,000 pregnancies
  • Varies by incidence HLA-DR3 and HLA-DR4
  • Predominant age: childbearing years
  • Predominant sex: female
Pediatric Considerations
  • ~5–10% of infants born to mothers with PG have cutaneous lesions that are usually self-limited and likely the result of transplacental passage of maternal IgG antibasement membrane zone autoantibodies.
  • Children born to mothers with PG are not at increased risk of autoimmune diseases.
Pregnancy Considerations
  • By definition, PG is a condition of pregnancy and puerperium; rarely seen in conjunction with hydatidiform mole and choriocarcinoma
  • Fetuses in mothers with PG are at risk for growth restriction and prematurity due to potential for placental insufficiency from immune response to placental antigens. Still birth is less common. Antenatal testing is indicated.
  • Treatment with systemic corticosteroids does not adversely affect pregnancy outcomes (1).
  • With each subsequent pregnancy, disease can recur at earlier onset. It is possible that subsequent pregnancies are unaffected as well.

Etiology and Pathophysiology

During pregnancy, patients develop IgG autoantibodies to placental proteins that cross-react with the same proteins in maternal skin (and potentially fetus).

  • Primary antigen is BP180 (type XVII collagen or BPAG2; a transmembrane protein required for dermal-epidermal adhesion); less frequent antigen is BP230.
  • Maternal IgG autoantibodies are presented to maternal immune system by aberrantly expressed HLA class II major histocompatibility complex (MHC II).
  • Autoantibodies initiate complement 3 (C3) fixation, complement and leukocyte activation which release proteolytic enzymes that separate the dermis and epidermis forming vesicles and bullae.
  • Higher association with HLA-DR3 and/or HLA-DR4
  • Not caused by herpes virus

Genetics
Genetic predisposition is possible given HLA-DR3 and HLA-DR4 association.

Risk Factors

  • Episode in prior pregnancy
  • Herpes simplex does not increase risk.

General Prevention

  • Avoid secondary infection of open skin lesions.
  • Estrogens may trigger future flare-up (e.g., oral contraceptives and menses).

Commonly Associated Conditions

  • Pregnancy
  • Rarely, trophoblastic tumors, hydatidiform mole, and choriocarcinoma
  • Other autoimmune diseases (e.g., thyroid disorders including Graves disease, pernicious anemia)

-- To view the remaining sections of this topic, please or purchase a subscription --

Citation

Stephens, Mark B., et al., editors. "Pemphigoid Gestationis." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816422/all/Pemphigoid_Gestationis.
Pemphigoid Gestationis. In: Stephens MB, Golding J, Baldor RA, et al, eds. 5-Minute Clinical Consult. 27th ed. Wolters Kluwer; 2019. https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816422/all/Pemphigoid_Gestationis. Accessed April 19, 2019.
Pemphigoid Gestationis. (2019). In Stephens, M. B., Golding, J., Baldor, R. A., & Domino, F. J. (Eds.), 5-Minute Clinical Consult. Available from https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816422/all/Pemphigoid_Gestationis
Pemphigoid Gestationis [Internet]. In: Stephens MB, Golding J, Baldor RA, Domino FJ, editors. 5-Minute Clinical Consult. Wolters Kluwer; 2019. [cited 2019 April 19]. Available from: https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816422/all/Pemphigoid_Gestationis.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Pemphigoid Gestationis ID - 816422 ED - Stephens,Mark B, ED - Golding,Jeremy, ED - Baldor,Robert A, ED - Domino,Frank J, BT - 5-Minute Clinical Consult, Updating UR - https://im.unboundmedicine.com/medicine/view/5-Minute-Clinical-Consult/816422/all/Pemphigoid_Gestationis PB - Wolters Kluwer ET - 27 DB - Medicine Central DP - Unbound Medicine ER -